Two weeks of hydrogen inhalation can significantly reverse adaptive and innate immune system senescence patients with advanced non-small cell lung cancer: a self-controlled study
Chen JB et al. · Med Gas Res. 2020;10(4):149–154.
Study at a glance
Human
Adults with advanced non-small cell lung cancer awaiting standard treatment
Nasal cannula or mask inhalation at 3,000 mL/min for 4 hours daily · 66.7% H₂ + 33.3% O₂ by volume.
4 hours daily for 2 weeks
Multiple immune-cell subset measures moved toward the ranges used by the authors after two weeks. No tumor response, progression or survival outcome was tested.
Uncontrolled 20-person biomarker study with many lymphocyte measures and only two weeks of follow-up. It does not establish cancer treatment benefit. Authors reported no financial support or conflicts.
What kind of evidence is this?
Human
Uncontrolled self-comparison study
Cancer research
Inhaled H₂
Information not yet classified
Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.
Methods
Adults with advanced non-small cell lung cancer awaiting standard treatment
20 participants
4 hours daily for 2 weeks
Nasal cannula or mask inhalation at 3,000 mL/min for 4 hours daily
Brown’s gas / oxyhydrogen — H₂ and O₂ co-delivered, not H₂ alone.
66.7% H₂ + 33.3% O₂ by volume.
2,001 mL/min H₂, calculated as 3,000 mL/min total mixed-gas flow × 66.7% H₂.
999 mL/min O₂, calculated as 3,000 mL/min × 33.3% O₂.
No concurrent control group; each participant was compared with their own baseline
Outcomes and reported result
Peripheral-blood adaptive and innate lymphocyte subsets
Multiple immune-cell subset measures moved toward the ranges used by the authors after two weeks. No tumor response, progression or survival outcome was tested.
Gas composition, flow, methods, principal results, funding and conflict statement checked in the open-access full text; independent appraisal remains incomplete.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
Uncontrolled 20-person biomarker study with many lymphocyte measures and only two weeks of follow-up. It does not establish cancer treatment benefit. Authors reported no financial support or conflicts.
Adults with advanced NSCLC awaiting standard treatment; not evidence for tumor control or improved survival.
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
PMID: 33380580 · DOI: 10.4103/2045-9912.304221
Open-access full text is available through PMC.
Open-access PMC full text and PubMed bibliographic record.
10 August 2026
Help people check the facts before they buy.
Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.